Finland· FI-REL-REL58438
Myozyme
A alglucosidase alfa product containing alglucosidase alfa, registered in Finland by Orifarm Oy. The same ATC class is registered in 14 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Alglucosidase alfa is registered in 14 of 19 countries.
Countries holding a registration under ATC A16AB07 (alglucosidase alfa), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 9 of them publish a price we can compare per daily dose
Alglucosidase alfa · ATC A16AB07
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of alglucosidase alfa costs, country by country.
Normalised to the WHO defined daily dose (0.1 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Alglucosidase alfa · price per daily dose (0.1 g)
USD · FX 28 Sept 2026
- CH Switzerland$1240.40
The record
At a glance
Fimea (Finland)- Active substance
- Alglucosidase alfa
- Manufacturer
- Orifarm Oy
- Country
- Finland (FI)
- ATC code
- A16AB07
- ATC class
- Alglucosidase alfa
- Defined daily dose
- 0.1 g, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Alglucosidase alfa in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaMYOZYMESanofi B.V., Amsterdam
- SpainMYOZYME 50 MG POLVO CONCENTRADO PARA SOLUCION PARA PERFUSIONSanofi B.V.
- United KingdomMyozyme 50mg powder for concentrate for solution for infusion vialsSanofi
- IrelandMyozyme 50 mg powder for concentrate for solution for infusionSanofi B.V.
- NetherlandsMyozyme, poeder voor concentraat voor oplossing voor i.v. infusie 50 mgGenzyme Europe BV
- NorwayMyozymeSanofi B.V.
- PolandMyozymeSanofi B.V.
- BelgiumMyozyme 50 mgSanofi
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Myozyme
- Liechtenstein · Myozyme
- Norway · Myozyme
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e84524b7-2e90-496b-b962-c36150ee51fe GET /v1/drugs/e84524b7-2e90-496b-b962-c36150ee51fe?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "0.1",
"form": "infuusiokuiva-aine konsentraattiliuosta varten",
"route": "Laskimoon",
"ddd_unit": "g",
"strength": "50 mg",
"atc_label": "alglukosidaasi alfa",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/06/333/001",
"fimea_rel_id": "REL58438",
"authorised_at": "2021-04-29"
}See everything about alglucosidase alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.